Medicina (Florence, Italy)最新文献_第10页

[Primary carcinoma of the liver and hepatitis C virus in Italy. A prospective study in patients with cirrhosis]. 意大利原发性肝癌和丙型肝炎病毒。一项针对肝硬化患者的前瞻性研究]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

S Bargiggia, A Piva, A Sangiovanni, F Donato

{"title":"[Primary carcinoma of the liver and hepatitis C virus in Italy. A prospective study in patients with cirrhosis].","authors":"S Bargiggia, A Piva, A Sangiovanni, F Donato","doi":"","DOIUrl":"","url":null,"abstract":"The possibility to detect the antibody to hepatitis C virus (HCV) has allowed to estimate the prevalence of this virus in patients with hepatic disease, mostly in those with hepatitis considered non-A non-B. Literature shows that HCV causes about 75% of cases of cryptogenic hepatitis and more than the 90% of post-transfusional hepatitis. Circumstantial evidence suggests the existence of a relationship between parenterally-transmitted non-A non-B hepatitis (PTH) and primary liver cancer (PLC). With the advent of anti-HCV, it is now possible to assess directly whether or not there is a relationship between PTH and PLC. So anti-HCV was looked for in the sera of 365 patients with cirrhosis prospectively followed-up for early detection the development of PLC, using an enzymatic immunoassay (ELISA Ortho DS). At baseline anti-HCV was detected in 221 patients (60%). During 5-39 month 53 patients developed PLC and anti-HCV was detected in 68% of them. The univariate analysis demonstrated that alcohol abuse, anti-HBs and anti-HBc were the only covariates that were significantly associated with an increase risk of developing PLC. When these factors were introduced in the step wise regression analysis, age and alcohol were found to be the only independent risk factors. The high prevalence of anti-HCV found in patients with cirrhosis and PLC suggests that HCV might play a role in this tumor; the frequent co-occurrence of HCV and HBV markers suggests that HCV-HBV coinfection might be pathogenically important; alcohol was the most important non-viral risk factor for PLC.","PeriodicalId":77570,"journal":{"name":"Medicina (Florence, Italy)","volume":"9 4","pages":"424-6"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13705043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Treatment of tuberculosis]. [治疗肺结核]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

M Covi, G Velluti

引用次数: 0

[Significance of tachyphylaxis induced by repeated bradykinin inhalation in bronchial asthma]. [反复吸入缓激肽致支气管哮喘快速反应的意义]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

R Polosa, S T Holgate

{"title":"[Significance of tachyphylaxis induced by repeated bradykinin inhalation in bronchial asthma].","authors":"R Polosa, S T Holgate","doi":"","DOIUrl":"","url":null,"abstract":"Bradykinin (Bk) is a potent bronchoconstrictor agent which may contribute to the pathogenesis of bronchial asthma. Recently we have shown that repeated bronchial challenge with this agonist in asthmatics produced a specific loss of responsiveness. In vitro studies suggest that this phenomenon may be due to generation of protective prostaglandins. In this study we investigated whether flurbiprofen (F) pretreatment inhibited Bk tachyphylaxis. The efficacy of F was demonstrated by the total suppression of whole blood TxB2 formation. In addition, a time-course study of the tachyphylactic response was carried out. Refractoriness in response to inhaled Bk occurred in all subjects. The mean PC20 Bk increased from 0.07 to 0.41 mg/ml with consecutive inhalation tests after placebo. Even in the presence of demonstrable cyclooxygenase inhibition, no effect of F was observed in inhibiting Bk tachyphylaxis the mean PC20 Bk still increasing from 0.10 to 0.47 mg/ml. Tachyphylaxis was still present at 6 h, but not in all subjects at 24 h. This study demonstrated that release of protective prostaglandins in the airway after Bk stimulation does not account for the loss of responsiveness following repeated exposure to Bk. At least 24 h should separate Bk inhalations to avoid tachyphylaxis. A possible mechanism of this phenomenon is discussed.","PeriodicalId":77570,"journal":{"name":"Medicina (Florence, Italy)","volume":"9 4","pages":"422-4"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13774870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Pulmonary infiltrate-eosinophilia syndrome. Description of a case]. 肺浸润-嗜酸性粒细胞增多综合征。案例描述]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

M Poggiato, R Roberti, F Rossi, U Visca

引用次数: 0

[Visualization of carotid and femoral atherosclerotic lesions using autologous lipoprotein reinjection containing apo-B marked with 131I: preliminary data]. [使用含有131I标记的载脂蛋白b的自体脂蛋白再注射显示颈动脉和股动脉粥样硬化病变:初步数据]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

G Lupattelli, M Fiacconi, G Orecchini, L Fedeli, D Siepi, L Pistola, G Deleide, R Palumbo

引用次数: 0

[Tricholeukemia associated with Kaposi's disease: presentation of a clinical case]. [与卡波西氏病相关的白血病:临床病例的介绍]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

L Temperilli, E Breda, A M Sidoti, A M Costa

引用次数: 0

[Nephrology]. (肾脏学)。

Medicina (Florence, Italy) Pub Date : 1989-10-01

M Abbate, G Remuzzi

{"title":"[Nephrology].","authors":"M Abbate, G Remuzzi","doi":"","DOIUrl":"","url":null,"abstract":"Advances in biomedical technology have contributed effectively to the resolution of basic and clinical problems in Nephrology. Most of our insights on glomerular diseases come from animal models. Antibodies against components of the extracellular matrix have been shown to induce glomerular changes in vivo and the non-collagenous NC1 domain of type IV collagen has been demonstrated to contain the Goodpasture antigen. New pathogenetic mechanisms of glomerular injury are suggested by studies on the interaction of antibodies with glomerular cell surface antigens. Gp330, a glycoprotein expressed at the surface of glomerular visceral epithelial cells, has been recognized to be the most relevant antigen of Heymann nephritis. Antibodies able to crosslink gp330 bind to the antigen at the base of foot processes and the resulting immune complexes are shed into the subepithelial space where they form electron dense deposits. The complement membrane attack complex (C5b-9) is likely to be directly responsible for epithelial cell injury and proteinuria in this model. Other cell surface antigens of the glomerular capillary wall, such as dipeptidyl dipeptidase IV, podocalyxin, podoendin, have been characterized. A novel model of glomerular injury comes from the demonstration that a non-complement fixing monoclonal antibody to a surface sialo-glycoprotein (SGP-115/107) binds to glomerular visceral epithelial cells and causes morphological changes which appear epitope-specific and complement and leukocyte-independent. The mechanisms responsible for the progression of renal disease to glomerular sclerosis have been extensively explored in the last years. Among the hemodynamic factors intraglomerular hypertension has been established to play an important part, at least in some models.(ABSTRACT TRUNCATED AT 250 WORDS)","PeriodicalId":77570,"journal":{"name":"Medicina (Florence, Italy)","volume":"9 4","pages":"467-74"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13839516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Treatment of mycobacteriosis]. 【分枝杆菌病的治疗】。

Medicina (Florence, Italy) Pub Date : 1989-10-01

M Covi, G Velluti, A Bisetti

引用次数: 0

[Current problems in assessing drug prices]. [目前评估药品价格的问题]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

C Lucioni

{"title":"[Current problems in assessing drug prices].","authors":"C Lucioni","doi":"","DOIUrl":"","url":null,"abstract":"Two reasons provide historical justification for controlling drug prices: safeguarding the consumer and safeguarding public demand. Due to the increased presence of the \"third payer\" in public health systems this second reason has become more important. Nevertheless, over the last decade, a third purpose has attached to public control of prices: promotion of drug manufacturers economic development. The justification offered for this is that development of pharmaceutical companies contributes to the economic growth of the host country by creating employment, exports and research activity. The situations in Germany, Great Britain and United States are often cited in support of this thesis. As a model for price policy in Italy, however, it has not been successful. The rapid growth of prices in fact has not created greater employment and the foreign exchange deficit has risen rapidly. In other words the growing cost of drugs to the National Health Service has not produced hoped-for economic benefits. It would therefore be opportune to modify the mechanisms of price control by seeking a better balance in the interests involved (safeguarding public demand versus manufacturers economic growth). Methodologies available point to the evaluation of the therapeutic utility of a drug as a useful tool for this purpose. By this method the price of a new drug may only be higher than that of a drug already on the market if its therapeutic utility (which does not coincide only with clinical effectiveness) is greater. Appropriate evaluation techniques of benefits deriving from a new drug (cost-effectiveness and cost-utility) do exist and can be taken into consideration in a new method of calculating drug price.","PeriodicalId":77570,"journal":{"name":"Medicina (Florence, Italy)","volume":"9 4","pages":"429-36"},"PeriodicalIF":0.0,"publicationDate":"1989-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13774871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Control using omeprazole in a case of upper digestive hemorrhage, induced by erosive uremic hemorrhagic gastritis resistant to conventional therapy]. [奥美拉唑对常规治疗无效的糜烂性尿毒症出血性胃炎致上消化道出血1例进行对照]。

Medicina (Florence, Italy) Pub Date : 1989-10-01

L Santucci, S Fiorucci, F Farroni, A Sicilia, G Mariotti, S Chiucchiù, P Filipponi, A Morelli

引用次数: 0